US Patent

US11583216 — Method of administering sotalol IV/switch

Method of Use · Assigned to University of Maryland Baltimore · Expires 2039-08-21 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for determining the optimum dose of sotalol by gradually titrating the dose to find the correct plasma concentration for a patient.

USPTO Abstract

Embodiments of the invention are broadly drawn to methods for determining an optimum dose of an antiarrhythmic drug, for example sotalol. In particular, the method involves titrating the dose of the drug gradually to determine the optimum plasma concentration for a patient, whether the patient has normal or abnormal renal function.

Drugs covered by this patent

sotalol-hydrochloride (SOTALOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3549`	—	sotalol-hydrochloride

Patent Metadata

Patent number: US11583216
Jurisdiction: US
Classification: Method of Use
Expires: 2039-08-21
Drug substance claim: No
Drug product claim: No
Assignee: University of Maryland Baltimore
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.